TP-317
Ulcerative Colitis (Inflammatory Bowel Disease)
Key Facts
About Thetis Pharmaceuticals
Thetis Pharmaceuticals is pioneering a novel therapeutic approach by developing TP-317, a stable, oral small molecule agonist of the BLT1 receptor based on the endogenous pro-resolving lipid mediator Resolvin E1 (RvE1). The company is targeting significant unmet needs in inflammatory bowel disease (IBD) and oncology, with a Phase 1a study in healthy volunteers completed and a Phase 1b study in ulcerative colitis patients planned for late 2026. Led by an experienced management team with deep expertise in pharmaceutical development and resolution biology, Thetis is a private, pre-revenue company advancing a platform that aims to restore tissue and immune homeostasis rather than broadly suppressing inflammation.
View full company profileAbout Thetis Pharmaceuticals
Thetis Pharmaceuticals is pioneering a novel therapeutic approach by developing TP-317, a stable, oral small molecule agonist of the BLT1 receptor based on the endogenous pro-resolving lipid mediator Resolvin E1 (RvE1). The company is targeting significant unmet needs in inflammatory bowel disease (IBD) and oncology, with a Phase 1a study in healthy volunteers completed and a Phase 1b study in ulcerative colitis patients planned for late 2026. Led by an experienced management team with deep expertise in pharmaceutical development and resolution biology, Thetis is a private, pre-revenue company advancing a platform that aims to restore tissue and immune homeostasis rather than broadly suppressing inflammation.
View full company profileTherapeutic Areas
Other Ulcerative Colitis (Inflammatory Bowel Disease) Drugs
| Drug | Company | Phase |
|---|---|---|
| BOOM-IBD2 Pivotal Trial | Boomerang Medical | Pivotal |